Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 11Other solid neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Melanoma 1Head and Neck Neoplasms 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 14Nivolumab 10atezolizumab 5durvalumab 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4avelumab 3Specimen Handling 3Radiosurgery 3Magnetic Resonance Spectroscopy 3temsirolimus 2poly ICLC 2fludarabine 2epacadostat 2enzalutamide 2cabozantinib 2budigalimab 2aldesleukin 2abiraterone 2Radiotherapy 2Interleukin-2 2Gemcitabine 2venetoclax 1utomilumab 1trastuzumab deruxtecan 1tislelizumab 1spartalizumab 1sargramostim 1rovalpituzumab tesirine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × rovalpituzumab tesirine × Dermatologic × Clear all
NCT03000257 2022-04-14

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Completed
182 enrolled
BreastDermatologicGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡